The longitudinal study of chronic sarcoidosis.

C. J. Johns, J. B. Zachary, M. I. MacGregor, J. L. Curtis, P. P. Scott, Peter Browne Terry

Research output: Contribution to journalArticle

Abstract

Although spontaneous remissions are frequent in sarcoidosis, chronic persistent disabling disease is also observed. This feature seems more frequent and more severe in black patients, as has been previously reported (10). The more extensive and severe the initial disease manifestations, the more likely it is that the disease will continue. Corticosteroids are usually beneficial and complications are infrequent. Delayed or interrupted treatment seems to allow progression or irreversible disease or both. Patient compliance is an obvious important factor. Relapses are frequent as treatment is withdrawn but are usually at least partially reversible. Some deterioration is observed with repeated relapses. Low dose daily prednisone (5-15 mg) seems to prevent relapses. Patient compliance is facilitated with daily treatment rather than alternate day therapy. Prolonged treatment for 10 to 15 or more years is often required. Chloroquine is particularly helpful in skin and mucosal disease. The necessity for long-term thoughtful management is obvious.

Original languageEnglish (US)
Pages (from-to)173-181
Number of pages9
JournalTransactions of the American Clinical and Climatological Association
Volume94
StatePublished - 1982
Externally publishedYes

Fingerprint

Sarcoidosis
Longitudinal Studies
Patient Compliance
Recurrence
Spontaneous Remission
Therapeutics
Chloroquine
Prednisone
Skin Diseases
Adrenal Cortex Hormones

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Johns, C. J., Zachary, J. B., MacGregor, M. I., Curtis, J. L., Scott, P. P., & Terry, P. B. (1982). The longitudinal study of chronic sarcoidosis. Transactions of the American Clinical and Climatological Association, 94, 173-181.

The longitudinal study of chronic sarcoidosis. / Johns, C. J.; Zachary, J. B.; MacGregor, M. I.; Curtis, J. L.; Scott, P. P.; Terry, Peter Browne.

In: Transactions of the American Clinical and Climatological Association, Vol. 94, 1982, p. 173-181.

Research output: Contribution to journalArticle

Johns, CJ, Zachary, JB, MacGregor, MI, Curtis, JL, Scott, PP & Terry, PB 1982, 'The longitudinal study of chronic sarcoidosis.', Transactions of the American Clinical and Climatological Association, vol. 94, pp. 173-181.
Johns, C. J. ; Zachary, J. B. ; MacGregor, M. I. ; Curtis, J. L. ; Scott, P. P. ; Terry, Peter Browne. / The longitudinal study of chronic sarcoidosis. In: Transactions of the American Clinical and Climatological Association. 1982 ; Vol. 94. pp. 173-181.
@article{9ea371a726234d90a2cfde2bf026c6fd,
title = "The longitudinal study of chronic sarcoidosis.",
abstract = "Although spontaneous remissions are frequent in sarcoidosis, chronic persistent disabling disease is also observed. This feature seems more frequent and more severe in black patients, as has been previously reported (10). The more extensive and severe the initial disease manifestations, the more likely it is that the disease will continue. Corticosteroids are usually beneficial and complications are infrequent. Delayed or interrupted treatment seems to allow progression or irreversible disease or both. Patient compliance is an obvious important factor. Relapses are frequent as treatment is withdrawn but are usually at least partially reversible. Some deterioration is observed with repeated relapses. Low dose daily prednisone (5-15 mg) seems to prevent relapses. Patient compliance is facilitated with daily treatment rather than alternate day therapy. Prolonged treatment for 10 to 15 or more years is often required. Chloroquine is particularly helpful in skin and mucosal disease. The necessity for long-term thoughtful management is obvious.",
author = "Johns, {C. J.} and Zachary, {J. B.} and MacGregor, {M. I.} and Curtis, {J. L.} and Scott, {P. P.} and Terry, {Peter Browne}",
year = "1982",
language = "English (US)",
volume = "94",
pages = "173--181",
journal = "Transactions of the American Clinical and Climatological Association",
issn = "0065-7778",
publisher = "American Clinical And Climatological Association",

}

TY - JOUR

T1 - The longitudinal study of chronic sarcoidosis.

AU - Johns, C. J.

AU - Zachary, J. B.

AU - MacGregor, M. I.

AU - Curtis, J. L.

AU - Scott, P. P.

AU - Terry, Peter Browne

PY - 1982

Y1 - 1982

N2 - Although spontaneous remissions are frequent in sarcoidosis, chronic persistent disabling disease is also observed. This feature seems more frequent and more severe in black patients, as has been previously reported (10). The more extensive and severe the initial disease manifestations, the more likely it is that the disease will continue. Corticosteroids are usually beneficial and complications are infrequent. Delayed or interrupted treatment seems to allow progression or irreversible disease or both. Patient compliance is an obvious important factor. Relapses are frequent as treatment is withdrawn but are usually at least partially reversible. Some deterioration is observed with repeated relapses. Low dose daily prednisone (5-15 mg) seems to prevent relapses. Patient compliance is facilitated with daily treatment rather than alternate day therapy. Prolonged treatment for 10 to 15 or more years is often required. Chloroquine is particularly helpful in skin and mucosal disease. The necessity for long-term thoughtful management is obvious.

AB - Although spontaneous remissions are frequent in sarcoidosis, chronic persistent disabling disease is also observed. This feature seems more frequent and more severe in black patients, as has been previously reported (10). The more extensive and severe the initial disease manifestations, the more likely it is that the disease will continue. Corticosteroids are usually beneficial and complications are infrequent. Delayed or interrupted treatment seems to allow progression or irreversible disease or both. Patient compliance is an obvious important factor. Relapses are frequent as treatment is withdrawn but are usually at least partially reversible. Some deterioration is observed with repeated relapses. Low dose daily prednisone (5-15 mg) seems to prevent relapses. Patient compliance is facilitated with daily treatment rather than alternate day therapy. Prolonged treatment for 10 to 15 or more years is often required. Chloroquine is particularly helpful in skin and mucosal disease. The necessity for long-term thoughtful management is obvious.

UR - http://www.scopus.com/inward/record.url?scp=0020353457&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020353457&partnerID=8YFLogxK

M3 - Article

C2 - 7186230

AN - SCOPUS:0020353457

VL - 94

SP - 173

EP - 181

JO - Transactions of the American Clinical and Climatological Association

JF - Transactions of the American Clinical and Climatological Association

SN - 0065-7778

ER -